INTRODUCTION
============

Pneumonia is the leading cause of infectious disease-related deaths in adults worldwide \[[@b1-kjim-2018-463]\]. Selecting appropriate pathogen-directed antibiotics in patients with community-onset pneumonia (CO-pneumonia) can decrease treatment cost, drug-related adverse events, and antibiotic resistance and allow for the narrowing of empiric antibiotic therapy \[[@b2-kjim-2018-463]-[@b4-kjim-2018-463]\]. Despite the development of diagnostic techniques for pneumonia, causative organisms have not been detected in more than half of the patients \[[@b5-kjim-2018-463]\]. Determining the etiology of pneumonia has remained challenging because of several reasons, including difficulties in obtaining good-quality sputum and the unreliability of subsequent culture results, low sensitivity of blood cultures, and the administration of antibiotics before sample collection \[[@b5-kjim-2018-463],[@b6-kjim-2018-463]\]. *Streptococcus pneumoniae* is the most frequently isolated pathogen; therefore, initial empirical antibiotic treatment regimens for most patients with community-acquired pneumonia (CAP) aim at covering *S. pneumoniae* \[[@b3-kjim-2018-463]\]. The early identification of *S. pneumoniae* may lead to the selection of more reliable pathogen-targeted antibiotics \[[@b3-kjim-2018-463]\].

The pneumococcal urinary antigen test (PUAT) is an assay widely used to identify the C-polysaccharide antigen common to all serotypes excreted into the urine using a membrane immunochromatographic test \[[@b7-kjim-2018-463]\]. In addition to the advantages of rapidity and simplicity, it has a high sensitivity and specificity over Gram stain and sputum cultures, as well as availability in patients who cannot demonstrate expectorated sputum \[[@b3-kjim-2018-463]\]. In addition, even after antibiotic therapy has been started, the PUAT has the ability to detect pneumococcal pneumonia \[[@b3-kjim-2018-463],[@b8-kjim-2018-463]\]. Current guidelines recommend that the PUAT can only be performed in patients with severe CAP or moderate- or high-severity pneumonia \[[@b3-kjim-2018-463],[@b9-kjim-2018-463]\].

To date, the clinical benefits derived from the results of PUAT have not been fully established \[[@b10-kjim-2018-463]\]. Thus, the aim of our study was to investigate the diagnostic performances of the PUAT, and the association between the results of PUAT and clinical outcomes in patients with CO-pneumonia.

METHODS
=======

Study design and population
---------------------------

We conducted a retrospective cohort study of patients with CO-pneumonia at a university affiliated medical center. Adult patients (aged ≥ 18 years) who were hospitalized with pneumonia between January 2012 and December 2015 were investigated. Patients were identified by the use of the international diagnostic codes version 10 to screen for possible cases as follows: J18.0 to 18.9 as representative codes of pneumonia in the primary discharge diagnosis \[[@b11-kjim-2018-463]\]. After reviewing the medical records and radiological findings of relevant patients, we confirmed the diagnosis of pneumonia as the presence of a new infiltrate on a chest radiograph and by clinical signs \[[@b2-kjim-2018-463]\]. We excluded the following types of patients: (1) those who were readmitted due to pneumonia within 10 days of leaving the hospital; (2) those who were transferred from other hospitals after hospitalization for \> 48 hours; (3) those with obstructive pneumonia; (4) those who had immunocompromised status, such as neutropenia (absolute neutrophil count \< 1,500 cells/μL) after chemotherapy or human immunodeficiency virus infection; (5) those who did not receive guideline-concordant antibiotic therapy; and (6) those who had hospital- acquired pneumonia (HAP). Although the concept of healthcare-associated pneumonia (HCAP) was eliminated in the revised 2016 American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA) guidelines for the management of HAP and ventilator-acquired pneumonia \[[@b12-kjim-2018-463]\], we included HCAP as a category of CO-pneumonia in the present study.

Urine samples were collected in the emergency department or ward in the first 24 hours to detect urinary antigens for *S. pneumoniae* using BinaxNOW (Binax Inc., Scarborough, ME, USA). According to the results of PUAT, we classified the study patients into positive and negative PUAT groups. Empiricalguideline-concordant antibiotics were maintained without regard to the results of tests. Demographics, radiological findings, laboratory findings, microbiological results, and clinical outcomes were compared between the two groups.

Ethical consideration
---------------------

Ethical committees approved to review clinical data of relevant patients obtained from medical records such as clinical parameters, laboratory, radiological, and microbiological findings. Information obtained during the study was kept confidential and only intended for research purpose.

The study protocol was approved by the Ethical Review Committee of Jeju National University Hospital (Institutional Review Board no. 2018-04-001). Informed consent was waived because of the retrospective nature of the study.

Microbiology and antibiotics
----------------------------

Sampling to determine the microbial etiology of pneumonia included sputum, tracheobronchial aspirates, bronchoalveolar lavage fluid, pleural fluid, or blood through a semi-quantitative manner. The antibiotic sensitivity of all isolates was determined using a disc diffusion method. Serologic tests were performed to detect antibodies against *Mycoplasma pneumoniae* or *Chlamydia pneumoniae*. A patient was considered to have a potentially drug-resistant (PDR) pathogen if one of the following pathogens was isolated: methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, extended-spectrum beta-lactamase (ESBL)-producing or carbapenem-resistant *Klebsiella pneumoniae* and *Escherichia coli*, *Acinetobacter baumannii*, or *Stenotrophomonas maltophilia* \[[@b13-kjim-2018-463]\].

Changes in antibiotic regimens were defined as either escalation or de-escalation after culture sensitivities or clinical stabilities were identified. Inappropriate antibiotic therapy was noted if the empirical antibiotic treatment was not effective against the identified pathogen based on *in vitro* susceptibility testing \[[@b14-kjim-2018-463]\]. Initial treatment failure was defined as death during initial treatment or a change of initial therapeutic agent after 48 hours due to clinical instability \[[@b15-kjim-2018-463]\]. Guideline-concordant antibiotic therapy for CAP was defined as antibiotic regimens recommended by the 2007 ATS/IDSA guidelines for CAP: specifically, beta-lactam plus macrolide or fluoroquinolone \[[@b3-kjim-2018-463]\]. Since the data of the present study were collected before the 2016 revised ATS/IDSA guidelines were released, guideline-concordant antibiotic therapy for HCAP was defined as antibiotic regimens recommended by the 2005 ATS/IDSA guidelines, i.e., anti-pseudomonal beta-lactam plus either a fluoroquinolone or an aminoglycoside, along with anti-MRSA coverage if risk factors were present \[[@b16-kjim-2018-463]\].

Statistical analyses
--------------------

Data are presented as median (interquartile range) for continuous variables and as a number (%) for categorical variables. Continuous variables were compared using the Student's *t* test for normally distributed variables and the Mann-Whitney *U* test for non-normally distributed variables. Categorical variables were compared using the Pearson chi-square test, and Fisher's exac*t* test was used when any cell contained less than five items. To evaluate the reliability of the PUAT, we calculated its sensitivity and positive and negative predictive values, using the following three different reference groups of patients as the gold standard: (1) definitive pneumococcal pneumonias (CO-pneumonia with *S. pneumoniae* isolated in blood or pleural fluid culture); (2) probable pneumococcal pneumonias (CO-pneumonia with *S. pneumoniae* as the predominant morphotype on Gram stain or culture of sputum, transtracheal aspirates, and bronchoalveolar lavage); and (3) all pneumococcal pneumonias (definite plus probable) \[[@b17-kjim-2018-463]\]. When determining specificity, we considered the control group as all patients without a diagnosis of pneumococcal pneumonia, including those with unknown etiology. We also calculated positive and negative likelihood ratios (LRs) as a measure of the extent to which the pretest odds were altered by the test results; low negative LR (\< 0.1) and high positive LR (\> 10) findings were considered to be useful for ruling out and ruling in decisions, respectively \[[@b18-kjim-2018-463]\].

To improve the balance of baseline characteristics and reduce the effects of selection bias and potential confounding in this retrospective cohort study, estimated propensity scores were used to match the positive PUAT group to the negative PUAT group. The propensity score was calculated by logistic regression analysis using the covariates of baseline characteristics ([Table 1](#t1-kjim-2018-463){ref-type="table"}). Standardized differences were estimated for all baseline covariates before and after matching to assess prematch imbalance and postmatch balance. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). All tests were two-sided, and *p* values of \< 0.05 were considered to be statistically significant.

RESULTS
=======

Study population
----------------

[Fig. 1](#f1-kjim-2018-463){ref-type="fig"} shows patient enrolment. Overall, 1,257 patients were analyzed, of whom 163 (13.0%) had positive PUAT results and 1,094 (87.0%) had negative PUAT results. The proportion of patients with positive PUAT results was similar in both CAP and HCAP groups (13.1% vs. 12.8%, *p* = 0.875). The microbiological methods by which *S. pneumoniae* was identified in 115 patients as a cause of CO-pneumonia are as follows: blood cultures in seven patients (6.1%), pleural fluid in two patients (1.7%), transtracheal aspiration in 15 patients (13.0%), bronchoalveolar lavage in six patients (5.2%), and sputum in 87 patients (75.7%). In two patients, *S. pneumoniae* was simultaneously identified in blood and sputum cultures, and PUAT was positive in seven of nine (77.8%) patients with definitive pneumococcal pneumonia. Also, in 108 patients with probable pneumococcal pneumonia, 58 (53.7%) tested positive. Taking into account both of the groups together (i.e., all pneumococcal pneumonia), the results of PUAT was positive in 65 patients (56.5%).

Baseline characteristics are presented in [Table 1](#t1-kjim-2018-463){ref-type="table"}. Prior to matching, patients in the positive PUAT group were more likely to reside in a nursing home or long-term care facility. In addition, the median white blood cell and C-reactive protein levels were higher in the positive PUAT group than in the negative PUAT group. The propensity score-matching process provided 161 pairs of patients with positive and negative PUAT findings and achieved a good balance for all baseline comorbidities, clinical parameters, and severity indexes.

Diagnostic accuracy of the PUAT in patients with CO-pneumonia
-------------------------------------------------------------

[Table 2](#t2-kjim-2018-463){ref-type="table"} shows the calculated values of sensitivity, specificity, positive and negative predictive values, and positive and negative LRs by the different methods. In patients with all pneumococcal pneumonia, the sensitivity of PUAT was 56.5% (95% confidence interval \[CI\], 47.0 to 65.7) and the specificity was 90.9% (95% CI, 89.0 to 92.6). Additionally, the positive predictive value was 39.9% (95% CI, 34.1 to 46.0) and the negative predictive value was 95.1% (95% CI, 94.1 to 96.0). Positive and negative LRs were 6.2 (95% CI,4.9 to 8.0) and 0.5 (95% CI, 0.4 to 0.6).

Microorganisms
--------------

[Table 3](#t3-kjim-2018-463){ref-type="table"} shows the distributions of microorganisms on the basis of the culture results. Overall etiology was established in 97 (59.5%) and 518 (47.3%) patients in the positive PUAT and the negative PUAT groups, respectively. Among patients with positive PUAT results, other microorganisms were identified in 36 (22.1%) patients using conventional methods. In both the full and propensity- matched cohorts, the rate of *S. pneumoniae* identified was significantly higher in the positive PUAT group (39.9% vs. 4.6%, *p* \< 0.001 and 39.5% vs. 4.3%, *p* \<0.001). Following propensity score matching, the rate of *Staphylococcus aureus* was statistically higher in the negative PUAT group (1.2% vs. 5.6%, *p* = 0.032).

Associations between the PUAT and clinical outcomes
---------------------------------------------------

The primary and secondary study outcomes are summarized in [Table 4](#t4-kjim-2018-463){ref-type="table"}. In the full cohort of 1,257 patients, there were no significant differences in 30-day mortality between groups (6.1% in the positive PUAT group vs. 8.2% in the negative PUAT group; odds ratio \[OR\], 0.73; 95% CI, 0.37 to 1.43; *p* = 0.357) ([Fig. 2A](#f2-kjim-2018-463){ref-type="fig"}). However, in the propensity-matched cohort, the 30-day mortality rates were lower in the positive PUAT group when compared with the negative PUAT group (5.6% vs. 17.4%; OR, 0.28; 95% CI, 0.13 to 0.62; *p* = 0.001) ([Fig. 2B](#f2-kjim-2018-463){ref-type="fig"}). In subgroup analysis for overall patients with severe pneumonia, the 30-day mortality was not significantly different between the positive and negative PUAT groups (23.1% vs. 33.1%, *p* = 0.297). On the other hand, in the propensity-matched cohort of severe pneumonia, the 30-day mortality rates were lower in the positive PUAT group (23.1% vs. 59.3%, *p* = 0.008).

In the full cohort, there were no significant differences in all secondary study outcomes between groups. In the propensity-matched cohort, the proportion of patients with PDR pathogens was significantly lower in the positive PUAT group (4.3% vs. 10.6%; OR, 0.39; 95% CI, 0.16 to 0.96; *p* = 0.034). Likewise, the proportion of patients with a change of antibiotics and failure of initial antibiotic therapy was also statistically lower in the positive PUAT group compared to the negative PUAT group (\[17.4% vs. 26.7%; OR, 0.58; 95% CI, 0.34 to 0.99; *p* = 0.044\] and \[14.9% vs. 30.0%; OR, 0.45; 95% CI, 0.26 to 0.79; *p* = 0.004\], respectively).

DISCUSSION
==========

In our study, we identified three major findings. First, approximately 13% of patients with CO-pneumonia had positive PUAT results, and the sensitivity and specificity values for the diagnosis of definitive, probable, and overall pneumococcal pneumonia were 77.8% and 87.3%, 53.7%, and 90.9%, and 56.5% and 90.9%, respectively. Second, the clinical parameters of the positive PUAT group were not worse than in the negative PUAT group. Third, in the propensity-matched cohort, the 30-day mortality rates were lower in the positive PUAT group.

In patients with CO-pneumonia, the selection of empirical antibiotic regimen is based on the prediction of the most common pathogens \[[@b3-kjim-2018-463],[@b9-kjim-2018-463]\]. Since the widespread use of pneumococcal conjugate vaccines was initiated, recent studies have reported a decline in *S. pneumoniae* as a cause of CAP \[[@b2-kjim-2018-463],[@b19-kjim-2018-463],[@b20-kjim-2018-463]\]. However, *S. pneumoniae* is still the most common cause at 5% to 21% among microorganisms leading to hospitalization in patients with CAP \[[@b7-kjim-2018-463],[@b21-kjim-2018-463]-[@b23-kjim-2018-463]\]. The PUAT is simple, rapid, and useful for detecting pneumococcal pneumonia when samples for culture cannot be obtained in a timely fashion or when antibiotic therapy has already commenced \[[@b3-kjim-2018-463],[@b8-kjim-2018-463]\]. Previously, a meta-analysis demonstrated that the pooled sensitivity and specificity of the PUAT for definitive pneumococcal pneumonia in the same clinical setting used in the present study were 75% and 80%, respectively \[[@b24-kjim-2018-463]\]. Our results indicated that the diagnostic performances of the PUAT for definitive pneumococcal pneumonia were comparable with the results of a meta-analysis \[[@b24-kjim-2018-463]\].

The PUAT has been reported to have a higher diagnostic yield in patients with severe pneumonia \[[@b25-kjim-2018-463]\]. Although a previous study revealed that the PUAT was more sensitive in patients with high-risk pneumonia as compared to those without (94% vs. 63%, *p* \< 0.001) \[[@b25-kjim-2018-463]\], the rate of severe pneumonia in our study was similar between both groups (16.0% vs. 15.1%, *p* = 0.773). And, while a recent multicenter USA study reported that patients with HCAP were less likely to have positive PUAT results than those with CAP \[[@b10-kjim-2018-463]\], there were no differences in positive PUAT results between the CAP and HCAP groups in our study.

The association between PUAT result and clinical outcomes in patients with CO-pneumonia has been investigated in a few studies \[[@b26-kjim-2018-463],[@b27-kjim-2018-463]\]. A large prospective study further demonstrated that positive PUAT results were significantly associated with 30-day mortality, intensive care unit admission, use of mechanical ventilation, treatment failure, and adverse outcomes in patients with bacteremic pneumococcal pneumonia \[[@b26-kjim-2018-463]\]. However, this study contained the possibility of selection bias, and patients with positive PUAT results were significantly worse in clinical parameters such as respiratory rates, arterial oxygen pressure, and pH levels, and multi-lobar involvement \[[@b26-kjim-2018-463]\]. In the present study, we found that 30-day mortality rates were significantly lower in the positive PUAT group after adjustment for initial presentations using the propensity score-matching process. Similarly, in a recent registry-based retrospective study using a modified CRB65 (confusion, respiratory rate, blood pressure, and age ≥ 65 years) score by subtracting 1 from the scoring system if the PUAT was positive, positive PUAT results were associated with lower risk of 30-day mortality \[[@b27-kjim-2018-463]\]. We additionally investigated the association between the PUAT results and secondary outcomes. In the propensity-matched cohort, the proportion of patients with PDR pathogens, changes in antibiotics, and failure rates of initial antibiotic therapy were significantly higher in the negative PUAT group than in the positive PUAT group.

Reasons for why PUAT is negative in some patients with pneumococcal pneumonia have been proposed to include the following: low levels of C-polysaccharide antigen and sequestration of the antigen by binding to serum antibodies in immune complexes, reduced urinary excretion of the antigen, delayed times from the onset of symptoms to diagnosis, and previous antibiotic treatment \[[@b26-kjim-2018-463]\]. We tried to find clinical parameters of false negative PUAT results. Compared to patients with true positive PUAT results, those with false negative PUAT results had chronic heart diseaseless frequently (18.5% vs. 8.0%, *p* = 0.049). However, because of the small sample size (n = 165) and low statistical power (*p* =0.049), we could not allow for this as a crucial parameter.

There remains controversy with regard to the change of antibiotics on the basis of the results of PUAT \[[@b28-kjim-2018-463],[@b29-kjim-2018-463]\]. In a prospective study including 219 patients with non-severe CAP, the targeted use of amoxicillin based on PUAT results was able to decrease antibiotic resistance and reduce the use of unnecessary antibiotics \[[@b28-kjim-2018-463]\]. In contrast, another randomized controlled trial reported that *S. pneumoniae*-targeted therapy with positive PUAT results increased the rate of clinical relapse compared with empirical therapy \[[@b29-kjim-2018-463]\]. Possible explanations for treatment failure may include the following: first, the possibility of polymicrobial infections cannot be excluded \[[@b29-kjim-2018-463]\]. Especially in the case of polymicrobial infections with PDR pathogens, narrowing the antibiotic treatment can lead to treatment failure. Second, a high proportion of pathogens remain unidentified in patients with CO-pneumonia. This means that it is difficult to predict the rate of polymicrobial infections. Third, pneumococcal capsular polysaccharides could react with othermicroorganisms such as *Staphylococcus*, *Streptococcus* species, and Gram-negative strains \[[@b30-kjim-2018-463]\]. Other microorganisms identified in patients with positive PUAT results through conventional methods, might be regarded as having cross-reactivity \[[@b30-kjim-2018-463]\]. Possible cross-reacting microorganisms could elicit treatment failure \[[@b30-kjim-2018-463]\]. Finally, the presence of drug-resistant *S. pneumoniae* may also be a plausible explanation \[[@b28-kjim-2018-463]\]. The emergence and spread of drug-resistant *S. pneumoniae* have been reported in recent years, and antibiotic resistance threatens the successful management of pneumococcal pneumonia \[[@b31-kjim-2018-463]\]. In a meta-analysis encompassing 10 studies that involved 3,430 patients, the combined relative risks of all-cause mortality for the penicillin-resistant *S. pneumoniae* groups was 1.29 (95% CI, 1.01 to 1.66) when compared with the penicillin-susceptible *S. pneumoniae* group \[[@b32-kjim-2018-463]\].

In principle, patients with positive PUAT results would have a good response to empirical guideline-concordant antibiotic therapy, which has been associated with a significant decrease in in-hospital mortality, length of hospital stay, and the duration of parenteral therapy \[[@b33-kjim-2018-463]\]. We maintained guideline-concordant empirical antibiotics without regard to the results of tests and investigated the association between the PUAT results and clinical outcomes in the present study.

The strength of our study is in the propensity score-matching process, although our subjects were a retrospective cohort. Meanwhile, there are some study limitations. First, because our study was conducted retrospectively involving patients admitted to a single institution, our data should be interpreted with caution. In particular, even though pneumococcal vaccination might produce a false positive result in the PUAT in clinical practice \[[@b34-kjim-2018-463]\], we could not identify the rate of pneumococcal vaccination due to the retrospective nature of the study. Second, we did not perform viral testing in most of the included patients. Mixed infections consisted of approximately 5% to 10% of the etiology for CAP in previous studies \[[@b20-kjim-2018-463],[@b27-kjim-2018-463]\]. Most polymicrobial agents in these studies were viral pathogens, which do not usually require specific antimicrobial therapy \[[@b20-kjim-2018-463],[@b35-kjim-2018-463]\]. Because we did not perform routine viral testing, the role of viral agents in CO-pneumonia might be underestimated in clinical outcomes. Third, previous studies have reported the relationship between serotype of *S. pneumoniae* and disease outcome \[[@b36-kjim-2018-463]\]. A pooled estimates for invasive pneumococcal disease demonstrated that serotypes 1, 7F, and 8 were associated with decreased risk ratios, while serotypes 3, 6A, 6B, 9N, and 19F were associated with increased risk ratios \[[@b36-kjim-2018-463]\]. However, the serotype of *S. pneumoniae* was not investigated in this clinical setting.

In conclusion, our study revealed that the PUAT had low sensitivity and high specificity for overall pneumococcal pneumonia. After baseline characteristics were adjusted through the propensity score-matching process, empirical guideline-concordant antibiotic therapy in CO-pneumonia was associated with a lower rate of 30-day mortality in patients with positive PUAT results.

KEY MESSAGE
===========

1\. The pneumococcal urinary antigen test (PUAT) had low sensitivity and high specificity for overall pneumococcal pneumonia.

2\. Baseline clinical parameters were similar between the positive PUAT and negative PUAT groups.

3\. In the propensity-matched cohort, the 30-day mortality rates were lower in the positive PUAT group.
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###### 

Baseline characteristics of the patients

  Characteristic                                                                     Entire cohort (n = 1,257)   Propensity score-matched cohort (n = 322)                                                             
  ---------------------------------------------------------------------------------- --------------------------- ------------------------------------------- ------- ------------------------ ------------------------ -------
  Age, yr                                                                            73 (66-81)                  72 (61-80)                                  0.124   73 (66-81)               74 (65-81)               0.683
  Male sex                                                                           105 (64.4)                  673 (61.5)                                  0.477   103 (64.0)               111 (68.9)               0.345
  Tube feeding                                                                       6 (3.7)                     45 (4.1)                                    0.794   6 (3.7)                  6 (3.7)                  1.000
  Hospitalization for 2 or more days in the past 90 days                             25 (15.3)                   207 (18.9)                                  0.271   25 (15.5)                29 (18.0)                0.551
  Residence in a nursing home or long-term care facility                             30 (18.4)                   139 (12.7)                                  0.047   30 (18.6)                29 (18.0)                0.885
  Recent outpatient intravenous therapy ≤ 30 days                                    6 (3.7)                     39 (3.6)                                    0.941   6 (3.7)                  4 (2.5)                  0.551
  Attendance at a dialysis center in the previous 30 days                            1 (0.6)                     24 (2.2)                                    0.238   1 (0.6)                  2 (1.2)                  1.000
  Comorbidity                                                                                                                                                                                                          
   Malignancy^[a](#tfn1-kjim-2018-463){ref-type="table-fn"}^                         29 (17.8)                   197 (18.0)                                  0.947   28 (17.4)                27 (16.8)                0.882
   Chronic liver disease^[b](#tfn2-kjim-2018-463){ref-type="table-fn"}^              10 (6.1)                    54 (4.9)                                    0.516   10 (6.2)                 11 (6.8)                 0.821
   Chronic heart disease^[c](#tfn3-kjim-2018-463){ref-type="table-fn"}^              23 (14.1)                   169 (15.4)                                  0.658   23 (14.3)                19 (11.8)                0.508
   Chronic kidney disease^[d](#tfn4-kjim-2018-463){ref-type="table-fn"}^             11 (6.7)                    126 (11.5)                                  0.068   11 (6.8)                 16 (9.9)                 0.315
   Diabetes mellitus^[e](#tfn5-kjim-2018-463){ref-type="table-fn"}^                  41 (25.2)                   251 (22.9)                                  0.533   40 (24.8)                48 (29.8)                0.317
   Chronic respiratory disease^[f](#tfn6-kjim-2018-463){ref-type="table-fn"}^        38 (23.3)                   295 (27.0)                                  0.324   38 (23.6)                38 (23.6)                1.000
   Central nervous system disorders^[g](#tfn7-kjim-2018-463){ref-type="table-fn"}^   49 (30.1)                   264 (24.1)                                  0.102   48 (29.8)                54 (33.5)                0.472
   Two or more comorbidities                                                         60 (36.8)                   436 (39.9)                                  0.458   59 (36.6)                66 (41.0)                0.423
  Clinical parameters                                                                                                                                                                                                  
  Altered mental state^[h](#tfn8-kjim-2018-463){ref-type="table-fn"}^                15 (9.2)                    100 (9.1)                                   0.980   15 (9.3)                 14 (8.7)                 0.846
  Respiratory failure^[i](#tfn9-kjim-2018-463){ref-type="table-fn"}^                 58 (35.6)                   359 (32.8)                                  0.484   57 (35.4)                62 (38.5)                0.564
  Sepsis or septic shock at onset^[j](#tfn10-kjim-2018-463){ref-type="table-fn"}^    22 (13.5)                   138 (12.6)                                  0.752   22 (13.7)                23 (14.3)                0.872
  Severe pneumonia                                                                   26 (16.0)                   165 (15.1)                                  0.773   26 (16.1)                27 (16.8)                0.881
  Intensive care unit admission                                                      21 (12.9)                   132 (12.1)                                  0.745   20 (12.4)                21 (13.0)                0.867
  Need for ventilation                                                               8 (4.9)                     69 (6.3)                                    0.487   8 (5.0)                  10 (6.2)                 0.628
  Radiological findings                                                                                                                                                                                                
   Multi-lobar involvement                                                           86 (52.8)                   504 (46.1)                                  0.127   84 (52.2)                83 (51.6)                0.921
   Pleural effusion                                                                  34 (20.9)                   189 (17.3)                                  0.264   32 (19.9)                31 (19.3)                0.888
  Laboratory findings                                                                                                                                                                                                  
   White blood cells, /mm^3^                                                         11,600 (8,600--16,100)      10,600 (7,675--14,100)                      0.011   11,600 (8,500--16,000)   11,800 (8,650--15,850)   0.877
   C-reactive protein, mg/dL                                                         12.0 (5.9--18.9)            9.7 (4.2--17.2)                             0.020   12.0 (5.8--18.7)         13.3 (6.3--21.7)         0.432
  Indices for disease severity                                                                                                                                                                                         
   CURB-65 score                                                                     1 (1--2)                    1 (1--2)                                    0.054   1 (1--2)                 1 (1--2)                 0.737
   PSI score                                                                         98 (76--123)                92 (70--121)                                0.080   98 (76--123)             99 (76--131)             0.610

Values are presented as median (interquartile range) or number (%). Septic shock was defined as sepsis with persisting hypotension requiring vasopressors to maintain a mean arterial pressure of ≥ 65 mmHg and having a serum lactate level of \> 2 mmol/L (18 mg/dL) despite adequate volume resuscitation.

PUAT, pneumococcal urinary antigen test; CURB-65, confusion, urea, respiratory rate, blood pressure, age ≥ 65 years; MRSA, methicillin-resistant *Staphylococcus aureus*; PSI, pneumonia severity index.

Malignancy includes active at the time of presentation or requiring anticancer treatment within the previous 5 years.

Chronic liver disease included preexisting viral or toxic hepatopathy at the time of pneumonia diagnosis.

Chronic heart disease was identified based on past history or administration of diuretics for the treatment of heart disease.

Chronic kidney disease included preexisting renal disease with documented abnormal serum creatinine levels.

Diabetes mellitus included a history of diagnosis of intolerance to glucose, hemoglobin A1c ≥ 6.5%, or treatment with oral hypoglycemic agents or insulin.

Chronic respiratory disease included simple chronic bronchitis, chronic obstructive pulmonary disease, and structural lung diseases such as bronchiectasis and interstitial lung diseases.

Central nervous system disorders included acute or chronic vascular or nonvascular encephalopathy with or without dementia.

Altered mental state was defined as Glasgow Coma Score ≤ 13 documented by the physician.

Respiratory failure was defined when partial pressure of oxygen in arterial blood (PaO~2~) was 60 mmHg or less or when the PaO~2~/fraction of inspired oxygen (FiO~2~) ratio was 300 mmHg or less.

Sepsis was defined as organ dysfunction identified as an acute change in the Sequential Organ Failure Assessment score of ≥ 2 consequent to pneumonia.

###### 

Diagnostic accuracy of the PUAT in patients with community-onset pneumonia

  Diagnosis of pneumococcal pneumonia   Sensitivity         Specificity         Positive PV         Negative PV         Positive LR      Negative LR
  ------------------------------------- ------------------- ------------------- ------------------- ------------------- ---------------- ----------------
  Definitive                            77.8 (40.0--97.2)   87.3 (85.4--89.1)   4.2 (3.0--6.1)      99.8 (99.4--100)    6.1 (4.2--9.0)   0.3 (0.1--0.9)
  Probable                              53.7 (43.9--63.3)   90.9 (89.1--92.5)   35.6 (30.0--41.6)   95.4 (94.5--96.2)   5.9 (4.6--7.6)   0.5 (0.4--0.6)
  Overall                               56.5 (47.0--65.7)   90.9 (89.0--92.6)   39.9 (34.1--46.0)   95.1 (94.1--96.0)   6.2 (4.9--8.0)   0.5 (0.4--0.6)

Values are presented as 95% confidence interval.

PUAT, pneumococcal urinary antigen test; PV, predictive value; LR, likelihood ratio.

###### 

Microorganisms isolated from the patients on the basis of culture results

  Variable                                                                      Entire cohort (n = 1,257)   Propensity score-matched cohort (n = 322)                                      
  ----------------------------------------------------------------------------- --------------------------- ------------------------------------------- ---------- ----------- ----------- ----------
  Microorganisms^[a](#tfn11-kjim-2018-463){ref-type="table-fn"}^                                                                                                                           
   Identified pathogens                                                         97 (59.5)                   518 (47.3)                                  0.004      95 (59.0)   85 (52.8)   0.262
  Gram-positive bacteria                                                                                                                                                                   
   *Streptococcus pneumoniae*                                                   65 (39.9)                   50 (4.6)                                    \< 0.001   64 (39.8)   7 (4.3)     \< 0.001
   *Staphylococcus aureus*                                                      2 (1.2)                     43 (3.9)                                    0.083      2 (1.2)     9 (5.6)     0.032
   Methicillin-sensitive *S. aureus*                                            0                           20 (1.8)                                    0.096      0           6 (3.7)     0.030
   Methicillin-resistant *S. aureus*                                            2 (1.2)                     23 (2.1)                                    0.762      2 (1.2)     3 (1.9)     1.000
   Other Gram-positive bacteria                                                 0 (0)                       17 (1.6)                                    0.151      0           2 (1.2)     0.498
  Gram-negative bacteria                                                                                                                                                                   
   *Pseudomonas aeruginosa*                                                     8 (4.9)                     46 (4.2)                                    0.680      8 (5.0)     6 (3.7)     0.585
   *Haemophilus influenza*                                                      1 (0.6)                     13 (1.2)                                    1.000      1 (0.6)     1 (0.6)     0.000
   *Klebsiella pneumoniae*                                                      9 (5.5)                     69 (6.3)                                    0.698      8 (5.0)     11 (6.8)    0.478
   ESBL (+)                                                                     1 (0.6)                     8 (0.7)                                     1.000      1 (0.6)     1 (0.6)     1.000
   ESBL (--)                                                                    8 (4.9)                     61 (5.6)                                    0.727      7 (11.5)    10 (6.2)    0.455
   *Acinetobacter species*                                                      0                           11 (1.0)                                    0.377      0           4 (2.5)     0.123
  Other Gram-negative species^[b](#tfn12-kjim-2018-463){ref-type="table-fn"}^   2 (1.2)                     14 (1.3)                                    1.000      2 (1.2)     1 (0.6)     1.000
   *Mycoplasma pneumonia*                                                       14 (8.6)                    61 (5.6)                                    0.130      14 (8.7)    9 (5.6)     0.279

Values are presented as number (%). Percentages refer to the division by the total number of patients.

PUAT, pneumococcal urinary antigen test; ESBL, extended-spectrum β-lactamase.

Allowed for overlapping.

Other Gram-negative species included *Escherichia coli, Enterobacter species, Serratia marcescens,* and *Legionella pneumophilia*.

###### 

The associations between the PUAT and clinical outcomes before and after propensity score matching

  Outcomes                                                                      Positive PUAT   Negative PUAT   *p* value   Effect size
  ----------------------------------------------------------------------------- --------------- --------------- ----------- -----------------------------------------------------------------------
  Primary outcome                                                                                                           
   30-day mortality, %                                                                                                      
    Crude (full cohort)                                                         6.1             8.2             0.357       0.73 (0.37 to 1.43)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
    Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^   5.6             17.4            0.001       0.28 (0.13 to 0.62)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
  Secondary outcomes                                                                                                        
   PDR pathogens^[c](#tfn15-kjim-2018-463){ref-type="table-fn"}^, %                                                         
    Crude (full cohort)                                                         6.7             9.8             0.216       0.67 (0.35 to 1.27)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
    Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^   4.3             10.6            0.034       0.39 (0.16 to 0.96)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
  Duration of antibiotic therapy, day                                                                                       
   Crude (full cohort)                                                          11.1 ± 6.0      11.6 ± 8.2      0.590       −0.50 (−1.54 to 0.54)^[d](#tfn16-kjim-2018-463){ref-type="table-fn"}^
   Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^    11.1 ± 6.0      11.9 ± 6.7      0.294       −0.80 (−2.19 to 0.59)^[d](#tfn16-kjim-2018-463){ref-type="table-fn"}^
  Change of antibiotics, %                                                                                                  
   Crude (full cohort)                                                          17.8            23.0            0.134       0.72 (0.47 to 1.11)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
   Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^    17.4            26.7            0.044       0.58 (0.34 to 0.99)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
  Use of inappropriate antibiotics, %                                                                                       
   Crude (full cohort)                                                          6.1             6.7             0.796       0.91 (0.46 to 1.81)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
   Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^    5.6             6.2             0.813       0.89 (0.35 to 2.26)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
  Failure of initial antibiotic therapy, %                                                                                  
   Crude (full cohort)                                                          15.3            21.5            0.071       0.66 (0.42 to 1.04)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
   Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^    14.9            30.0            0.004       0.45 (0.26 to 0.79)^[a](#tfn13-kjim-2018-463){ref-type="table-fn"}^
  Length of hospital stay, day                                                                                              
   Crude (full cohort)                                                          10.8 ± 12.0     9.6 ± 8.8       0.737       1.20 (−0.71 to 3.11)^[d](#tfn16-kjim-2018-463){ref-type="table-fn"}^
   Propensity score matching^[b](#tfn14-kjim-2018-463){ref-type="table-fn"}^    10.9 ± 12.1     12.3± 10.5      0.153       −1.40 (−3.87 to 1.07)^[d](#tfn16-kjim-2018-463){ref-type="table-fn"}^

Values are presented as percentage or mean ± SD.

PUAT, pneumococcal urinary antigen test; PDR, potentially drug-resistant; CURB-65, confusion, urea, respiratory rate, blood pressure, age ≥ 65 years; ESBL, extended-spectrum β-lactamase.

Odds ratio (95% confidence interval).

The variables included as covariates in the propensity score matching were age; sex; tube feeding; comorbidities (e.g., malignancy, chronic liver disease, chronic heart disease, chronic kidney disease, diabetes mellitus, chronic respiratory disease, central nervous system disorders, and two or more comorbidities); altered mental state; respiratory failure; sepsis or septic shock; intensive care unit admission; need for ventilation; antibiotic use before admission; multi-lobar involvement; pleural effusion; white blood cells; C-reactive protein; CURB-65 score; and pneumonia severity index.

PDR pathogens included methicillin-resistant *Staphylococcus aureus, Pseudomonas species, Acinetobacter species, Stenotrophomonas maltophilia,* and ESBL-producing Enterobacteriaceae.

Mean difference (95% confidence interval).

[^1]: These authors contributed equally to this work.
